Videos

Lawrence F. Eichenfield, MD; Jeffrey M. Bienstock, MD, FAAP; Peter A. Lio, MD; and Elizabeth A. Swanson, MD, discuss whether children outgrow atopic dermatitis and advice for the management of disease.

The role of multidisciplinary management in diagnosing atopic dermatitis and when patients typically seek care.

An expert in dermatology discusses the potential impact of non-medical switching to biosimilars and generic formulations on safety and efficacy profiles.

Adam Friedman, MD, FAAD defines non-medical therapeutic switching and discusses common tactics payors use to pressure practitioners and patients to switch.

Optimizing care and managing challenges for patients with ADHD during the COVID-19 pandemic and advice for clinicians educating patients and families on disease management.

Rakesh Jain, MD, MPH, shares his thoughts on whether drug holidays are appropriate for children taking medication for ADHD.

A discussion on the recent development of investigational serotonin norepinephrine modulating agent (SNMA), SPN-812, for the treatment of ADHD in adults.

Rakesh Jain, MD, MPH, considers the evidence-based recommended hierarchy in the choice of medications for the treatment of pediatric and adult ADHD.

Andrew J. Cutler, MD, reviews currently available stimulants and nonstimulants as well as their safety and efficacy for the treatment of ADHD.

Andrew J. Cutler, MD, discusses the benefits of cognitive behavior therapy (CBT), exercise, and family therapy for the management of ADHD.

Andrew J. Cutler, MD, and Rakesh Jain, MD, MPH, comment on comorbid psychiatric disorders complicating the diagnostic process for ADHD and review unmet needs.

A review of common signs and symptoms prompting testing for ADHD and approaching ADHD diagnosis in adults.

Updates in the AAP (American Academy of Pediatrics) and SDBP (Society for Developmental and Behavioral Pediatrics) guidelines for the assessment, evaluation, and treatment of ADHD in children and adolescents.

Standardized screening is used by support staff to assess developmental milestones to assist in the recognition of spinal muscular atrophy (SMA).  

Screening of newborns for spinal muscular atrophy (SMA) has been implemented in 33 states. The signs and symptoms leading a pediatrician to a diagnosis of SMA are discussed.

Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, discuss the challenges and unmet needs psychiatrists and their teams face when treating patients with schizophrenia and their multiple comorbidities.

Joe Avelino, RN, BSN, MHSA, CPHQ, and Henry Nasrallah, MD, review schizophrenia and the needs of these patients.

Valerie Callender, MD, gives an overview of her practice and discusses the challenges during the COVID-19 pandemic.

Jeffrey Bratberg, PharmD, FAPhA, leads discussion tackling common opioid-related misconceptions as well as unintended consequences of the opioid crisis.

Jeremy Adler, DMSc, PA-C, DFAAPA, leads discussion on elements that negatively impacts the quality of care for patients requiring pain management.

Jeffrey Bienstock, MD, FAAP, identifies the various triggers causing flare-ups for atopic dermatitis in patients.

Rakesh Jain, MD, MPH, comments on factors pre-disposing children and adults to ADHD and the impact of disease on patients’ and caregivers’ quality of life (QoL).

Andrew J. Cutler, MD, provides an overview of the different presentations of attention deficit hyperactivity disorders (ADHD) and the clinical burden on children and adults.

Garey H. Noritz, MDwalks us through a virtual pediatric neurological exam and notes examination findings that may be identified in an infant with Spinal Muscular Atrophy (SMA).

Diana Castro, MD walks us through a pediatric neurological exam and notes examination findings that may be identified in an infant with Spinal Muscular Atrophy (SMA).

Experts discuss opioid crisis complexities, such as the able to manage pain appropriately and the impact of social and structural determinates of health.